1. Draw 1 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
5. Use within 28 days of reconstitution. At 5.0 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe.

Tirzepatide is a novel dual agonist that simultaneously activates GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety through central appetite regulation. The added GIP activity appears to synergistically amplify metabolic effects beyond GLP-1 alone, contributing to superior weight reduction observed in clinical trials. Its approximately 5 day half-life enables convenient once-weekly administration.

• Glycemic control: Significant HbA1c reductions in type 2 diabetes trials.
• Weight reduction: Clinical trials report substantial body-weight loss (up to ~11 kg more than GLP-1 RA
  comparators over 26 weeks at higher doses).
• Cardiovascular markers: Improvements in lipid profiles and blood pressure observed in some studies.
• Common side effects: Gastrointestinal (nausea, diarrhea, vomiting, constipation), typically mild to
  moderate and dose-dependent; gradual titration reduces incidence.
• Injection-site reactions: Occasional mild redness or irritation at subcutaneous injection sites.